Immunotherapy has been an emerging and exciting therapeutic area that has experienced massive growth in terms of research and development expenditures and the sheer number of clinical trials. Analysts have projected that the cancer immunotherapy market will increase to nearly $9 billion across the world's major pharmaceutical markets by 2022 (the whole cancer drug market is expected to reach $111.9bn (Allied Market Research), so immuno-oncology will be within the region of 10% market share for this type of therapeutic).
Immunotherapies may eventually be used in as many as 60% of cases of advanced cancer, and are likely to see their first applications in melanoma, NSCLC, and B-cell malignancies. Either alone or in combination therapies, immunotherapies may produce long-term remissions or even cures for cancers that have been uniformly fatal until very recently.
Take a look at who was in the room at our industry’s leading exhibition last year – CLICK HERE.